Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND & AIMS There are few data from longitudinal studies of trends in primary biliary cholangitis (PBC) among patients under routine clinical care in the United States. We collected data from the Fibrotic Liver Disease consortium to investigate changes in the incidence and prevalence of PBC and the effects of patient demographics, clinical features, and treatment on mortality. METHODS We collected demographic and clinical data for the general patient population as well as PBC patients receiving care from 11 health systems in different regions of the United States (Northeast, Midwest, Northwest, and South) from January 1, 2003, through December 31, 2014. Annual percentage changes in PBC prevalence and incidence were estimated using join‐point Poisson regression. Differences based on race, age, and gender were calculated with rate ratios. All‐cause mortality was estimated using Cox regression with adjustment for patient characteristics and treatment with ursodeoxycholic acid (UDCA). Propensity scores were used to adjust for treatment selection bias. Analyses were adjusted by geographic regions. RESULTS In our racially diverse cohort of 3488 patients with PBC (21% Hispanic, 8% African American, 7% Asian American), 70% had ever received UDCA. From 2006 through 2014, the prevalence of PBC increased from 21.7 to 39.2 per 100,000 persons. Adjusted annual percentage changes in prevalence differed among age groups (≤40 y, 41–50 y, 51–60 y, 61–70 y, and >70 y), ranging from 3.0% to 7.5% (P < .05). Incidence did not change significantly during the study period (4.2 vs 4.3 per 100,000 person‐years in 2006 and 2014, respectively; P = .98). Ratios of prevalence for women vs men (3.9:1) and incidence for women vs men (3.2:1) were consistent over the study period. Among African Americans, the prevalence of PBC increased from 16.9 to 30.8 per 100,000 during the study period, and annual incidence ranged from 2.6 to 6.6 per 100,000 person‐years. In adjusted analyses, an increased level of alkaline phosphatase at baseline was associated with significantly higher mortality (adjusted hazard ratios [aHR], 1.24; 95% CI, 1.04–1.48 for patients with levels 1–2 times the upper limit of normal and aHR, 2.27; 95% CI, 1.88–2.73 for patients with levels more than 3 times the upper limit of normal). UDCA treatment was associated with significantly reduced mortality (aHR, 0.57; 95% CI, 0.52–0.64). CONCLUSIONS In an analysis of data from patients receiving routine clinical care in Fibrotic Liver Disease Consortium health systems, we found that the prevalence of PBC increased from 2004 through 2014, despite steady incidence. Patient demographic and clinical characteristics, as well as UDCA treatment, affected mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498
Self-citationLammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Self-citationEpidemiology and natural history of primary biliary cirrhosis in a U.S. community
Kim, W. R., Lindor, K. D., Locke, G. R., Therneau, T. M., Homburger, H. A., Batts, K. P., Yawn, B. P., Petz, J. L., Melton, L. J., & Dickson, E. R. (2000) · Gastroenterology · doi:10.1053/gast.2000.20197 · Cited by 349
Self-citationEffects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis
Lindor, K., Therneau, T., Jorgensen, R., Malinchoc, M., & Dickson, E. (1996) · Gastroenterology · doi:10.1053/gast.1996.v110.pm8613058 · Cited by 228 · cited 1×
“A recent review of data derived from clinical trials found no benefit of UDCA treatment on mortality,(4) whereas a large US placebocontrolled study with 3 years of follow-up evaluation showed that UDCA treatment improved survival.(5) A recent major editorial(6) emphasized the value of “real world evidence” regarding d…”
BackgroundSelf-citationEvolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis
Lleo, A., Jepsen, P., Morenghi, E., Carbone, M., Moroni, L., Battezzati, P. M., Podda, M., Mackay, I. R., Gershwin, M. E., & Invernizzi, P. (2016) · Scientific Reports · doi:10.1038/srep25906 · Cited by 186 · cited 6×
“Although there are few studies of PBC trends in the United States, studies from Europe and Asia reported a generally steady to slightly increasing PBC prevalence in the past decade, with roughly 4 to 9 times higher prevalence among women compared with men.(2,3) However, because these studies used data drawn from natio…”
MethodResultInfluentialRising incidence and prevalence of primary biliary cirrhosis: a large population-based study
Boonstra, K., Kunst, A. E., Stadhouders, P. H., Tuynman, H. A., Poen, A. C., van Nieuwkerk, K. M. J., Witteman, E. M., Hamann, D., Witteman, B. J., Beuers, U., et al. (2014) · Liver International · doi:10.1111/liv.12434 · Cited by 112
Cited by
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis
Moon, A. M., Singal, A. G., & Tapper, E. B. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.07.060 · Cited by 1,150
Primary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
The challenges of primary biliary cholangitis: What is new and what needs to be done
Terziroli Beretta-Piccoli, B., Mieli-Vergani, G., Vergani, D., Vierling, J. M., Adams, D., Alpini, G., Banales, J. M., Beuers, U., Björnsson, E., Bowlus, C., et al. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102328 · Cited by 114
Self-citationContemporary epidemiology of primary biliary cholangitis
Colapietro, F., Bertazzoni, A., & Lleo, A. (2022) · Clinics in Liver Disease · doi:10.1016/j.cld.2022.06.001 · Cited by 43
Gungabissoon, U., Gibbons, D. C., Requena, G., Ribeiro de Souza, A., & Smith, H. (2022) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2021-000857 · Cited by 20
Metadata
- Authors
- Lu, M., Zhou, Y., Haller, I. V., Romanelli, R. J., VanWormer, J. J., Rodriguez, C. V., Anderson, H., Boscarino, J. A., Schmidt, M. A., Daida, Y. G., Sahota, A., Vincent, J., Bowlus, C. L., Lindor, K., Zhang, T., Trudeau, S., Li, J., Rupp, L. B., & Gordon, S. C.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 16
- Issue
- 8
- Pages
- 1342-1350.e1
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2777791186
- Cited by
- 138
- References
- 6
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. https://app.cochat.ai/papers/10.1016/j.cgh.2017.12.033
- The paper
- Lu, M., Zhou, Y., Haller, I. V., Romanelli, R. J., VanWormer, J. J., Rodriguez, C. V., Anderson, H., Boscarino, J. A., Schmidt, M. A., Daida, Y. G., Sahota, A., Vincent, J., Bowlus, C. L., Lindor, K., Zhang, T., Trudeau, S., Li, J., Rupp, L. B., & Gordon, S. C. (2018). Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2017.12.033
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.